ARTICLES

Filter  
Active filters 0
Remove
  

Refine your searches by:

Collections
Education
History
Research
Biology
Medicine / Sub specialtie
Social Sciences
Public health
Literature
Religion
Pure sciences
all records (73)

Languages
English
Spanish
Portuguese
German

Countries
Indonesia
Brazil
USA
South Africa
Denmark
Spain
Ukraine
Argentina
Colombia
Chile
all records (72)

Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
all records (24)

Filter  
 
2.170.467  Articles
1 of 217.048 pages  |  10  records  |  more records»
Background: Unintentional weight loss is a hallmark of frailty and is associated with poor outcomes in older adults with type 2 diabetes. As such, the role of pharmacological therapies that facilitate weight loss – namely, sodium- glucose co-transpor... see more

Glucagon like peptide-1 receptor agonists (GLP-1RAs) are a new class of injectable agent used in the management of type 2 diabetes (T2DM). In the UK, NICE approved the use of GLP-1RAs in combination with metformin and sulphonylurea in people with T2DM who... see more

Objectives: To investigate the effects of a glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide on podocytes, inflammation, and oxidative stress in patients with diabetic nephropathy (DN).Methods: Eighty-four DN patients treated by the departme... see more

Background: American Diabetes Association (ADA) made conspicuous changes in its 2019 Standards ofCare Diabetes guidelines by choosing Glucagon like Peptide 1 (GLP1) receptor agonists and SodiumGlucose co-transporter 2 (SGLT2) inhibitors as the second line... see more

Injectable glucagon-like peptide-1 receptor agonists (GLP-1ras) have the distinct advantage of promoting weight loss as well as lowering glucose in type 2 diabetes. Treatment with a GLP-1ra is costly, thereby necessitating a restriction on widespread use,... see more


The glucose intolerance of diabetes aggravates atherosclerosis indirectly through its effect on lipids and endothelial function. The cardiovascular (CV) impact of this metabolic disturbance is seen in the worsening of atherosclerotic vascular disease pred... see more

Background and Objective: GLP-one receptor agonists are amongst the unique antidiabetes medications that have significant metabolic and cardiovascular benefits in addition to glucose lowering effect. To best of our knowledge, there is no published data on... see more

-

1 of 217.048 pages  |  10  records  |  more records»